Section V · status on the record
KPV Legal Status, FDA 503A Category, and Compounding Access
Where KPV actually stands under U.S. compounding law — stated in the present tense, cited to FDA, with the active 2026 review described as exactly what it is.
The short version
Here is KPV legal status in plain terms. KPV is a research peptide. It is not an FDA-approved drug for anything. Under U.S. law, a raw drug ingredient can be used by compounding pharmacies only if it clears one of a few specific bars — and KPV is still being evaluated for one of them, not cleared. The forward-looking part is real and worth stating: KPV is named by FDA itself on the public agenda of a July 2026 advisory committee meeting that will discuss whether it should go on the compounding "bulks list." That is a scheduled discussion, not a decision, and not a change in its current status.
The current FDA position on KPV
KPV legal status starts from a fixed, citable fact: KPV — the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH) — is a research peptide and is not an FDA-approved drug for any indication [16]. There is no approved KPV medicine and no approved therapeutic use.
The compounding question is governed by federal law. Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance (an active pharmaceutical ingredient used as a starting material, rather than a finished approved drug) may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [16]. Substances not yet on that list are evaluated by FDA through a public nomination process informed by the Pharmacy Compounding Advisory Committee (PCAC) [16].
KPV is one of the bulk drug substances FDA has scheduled for PCAC evaluation [17]. Being under evaluation is not the same as being on the bulks list, and it is not the same as being approved for compounding [16][17]. This page is general information about the regulatory landscape. It is not medical or legal advice, and it is not an offer to sell or supply any substance.
Access is under active FDA review and may expand in 2026
The forward-looking fact is genuine, and it is stated with care. KPV appears individually on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" — evaluated in both its free base and acetate forms [17]. The same agenda also lists BPC-157, TB-500, and MOTs-C [17].
That is the whole of what can be asserted: a scheduled evaluation and discussion. It is not a listing decision, it is not a reclassification, and it is not a change in current status [17]. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by the PCAC; being discussed by the committee is a step in evaluation, not a final listing decision [16]. The outcome of the July 2026 meeting is unknown and is not assumed here [17].
A note on what this page does not claim. Some commercial and clinic sources have reported an early-2026 reclassification of compounding peptides, and some assert specific 2026 dates on which substances were "removed" from a safety-risk category. Those reports could not be confirmed from an authoritative FDA source, so this page does not present any reclassification or removal as having occurred [16]. KPV's present-tense status is what FDA's own public materials support: a research peptide, not approved, scheduled for PCAC evaluation [16][17].
How legally compounded peptide access works
Under the U.S. Federal Food, Drug, and Cosmetic Act, drug compounding runs through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient; Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight [16].
In practice, a legally compounded medication is prepared only after an individual patient is evaluated by a licensed prescriber who determines a compounded preparation is appropriate and issues a valid, patient-specific prescription [16]. The preparation is then made by a state-licensed 503A compounding pharmacy or, for larger volumes, an FDA-registered 503B outsourcing facility [16]. Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription issued, but it does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate prescriber-patient relationship and a valid prescription [16].
The ingredient-eligibility caveat is the operative one. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or is on the relevant FDA bulks list [16]. KPV is none of these as its status presently stands — it is under PCAC evaluation, not on the bulks list — and a substance that is not yet eligible is not eligible for routine 503A compounding while that status stands [16][17]. This is described in general terms; this page names no pharmacy, clinic, telehealth provider, or vendor, gives no dosing, and describes no way to obtain a substance outside the lawful framework.
Legal-status questions
Direct, present-tense answers, cited to FDA. The fuller question set is on common KPV questions.
Is KPV legal?
KPV is a research peptide and is not an FDA-approved drug for any indication [16]. It is sold by chemical suppliers for laboratory research use only and has no approved human therapeutic use. This is general regulatory information, not legal advice, and not an offer to supply anything.
Can you get KPV from a compounding pharmacy?
Lawful compounded access requires the active ingredient to be eligible under the 503A/503B framework — via a USP/NF monograph, status as a component of an approved drug, or inclusion on the FDA bulks list [16]. KPV is none of these as its status stands; it is under PCAC evaluation, not on the bulks list [16][17]. This is general information, not advice.
What is the FDA 503A status of KPV?
KPV is not on the FDA 503A bulks list and is not an FDA-approved drug; it is a research peptide FDA has scheduled for evaluation [16]. KPV is individually named on the July 23-24, 2026 PCAC agenda (free base and acetate) as a bulks-list candidate — a scheduled discussion under evaluation, not a listing decision or a change in current status [17].